Round voting button logo

H.R.9559

IBOGAINE Act Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act

Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act

Introduced·6/30/26

The IBOGAINE Act aims to accelerate the development and access to psychedelic drugs for treating serious mental illnesses.

The IBOGAINE Act, officially named the Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act, seeks to expedite the development and access to psychedelic drugs, specifically ibogaine, for treating serious mental illnesses. The Act mandates the Attorney General to determine whether to reschedule ibogaine from Schedule I to Schedule II under the Controlled Substances Act. It also establishes a special registration process for physicians to administer eligible investigational drugs in Schedule I to eligible patients.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Energy And Commerce Committee
Next
Committee decision

Sponsors

D
1
3
RRR
Democratic CaucusRepublican Caucus

History

Jun 30

House

Introduced in House

Jun 30

House

Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.